Join
Live feed
·
PRReleasevia Quantisnow
Alector Inc. logo
GSK plc logo

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
ALEC· Alector Inc.GSK· GSK plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALEC (Alector Inc.), GSK (GSK plc) and more on Quantisnow.

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease | Quantisnow